Insmed (INSM)
(Delayed Data from NSDQ)
$26.18 USD
+0.03 (0.11%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $26.17 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Insmed (INSM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.60 | $55.00 | $35.00 | 66.54% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Insmed comes to $43.60. The forecasts range from a low of $35.00 to a high of $55.00. The average price target represents an increase of 66.54% from the last closing price of $26.18.
Analyst Price Targets (15)
Broker Rating
Insmed currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 16 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 15 | 14 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/27/2024 | Guggenheim Securities | Vamil Divan | Strong Buy | Strong Buy |
2/16/2024 | Cantor Fitzgerald & Co | Jennifer Kim | Strong Buy | Strong Buy |
2/11/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
10/30/2023 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
9/7/2023 | Evercore Partners | Liisa A Bayko | Not Available | Strong Buy |
9/6/2023 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 16 |
Average Target Price | $43.60 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 252 |
Current Quarter EPS Est: | -1.21 |